anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For Arm 3, the same 20 subjects will be administered goldenseal (1.1 g) orally three times daily for 27 days. On the 28th day, participants will be administered the goldenseal three times daily, as well as the single dose of midazolam (as described in Arm 1). Plasma and urine will be collected in a manner identical to that in Arm 1. A designated washout period for midazolam will not be necessary to separate Arm 3 from Arm 2 since there will be 27 days of goldenseal administration prior to the midazolam administration.
BACKGROUND: This study assesses the feasibility, safety, and clinical utility of vessel-sparing approach in totally robotic sigmoidectomy for adenocarcinoma.
MATERIAL AND METHODS: A comprehensive protocol for completely vessel-sparing robotic sigmoidectomy (VsRS) was established at the authors' institution from January 2019 through December 2020. Surgical and pathological outcomes were indagated and compared with results of current literature.
RESULTS: The study population consisted of 34 patients. The median number of examined lymph nodes (ELN) was 21 (range 15-28); the median number of positive lymph nodes (PLN) was 0 (range 0-8). Mean operative time was 240 min (sd 43.56, range 180-360 min), and conversion to open rate was 0%. Anastomotic leak rate was 0%. The median follow-up period was 28 months CONCLUSION: This pilot series represents a significant step forward in the development of completely vessel-sparing sigmoidectomy for adenocarcinoma. The study demonstrates the safety and feasibility of this innovative approach, which aims to achieve oncological radicality while preserving vital vascular structures. Notably, the postoperative outcomes observed in this study were comparable to those reported in the existing literature for the current standard of care at high-volume centers. Nevertheless, further validation through prospective and controlled investigations is essential before this technique can be fully incorporated into clinical practice.
The patients in Group N will not receive any intervention. In the intervention and control groups, block sites will be covered with dressings, and patients and other health care workers will be blinded to treatment allocation. The pain intensity during rest and motion will be evaluated with the 0-10 Numeric Rating Scale (NRS). Patients will receive standard multimodal analgesia comprising paracetamol, tenoxicam, and tramadol.
Bortezomib is associated with thrombocytopenia and neutropenia that follow a cyclical pattern with nadirs occurring following the last dose of each cycle and typically recovering prior to initiation of the subsequent cycle. The cyclical pattern of platelet and neutrophil decreases and recovery remain consistent in the studies of multiple myeloma and mantle cell lymphoma, with no evidence of cumulative thrombocytopenia or neutropenia in the treatment regimens studied. 

Monitor complete blood counts (CBC) frequently during treatment with Bortezomib for injection. Measure platelet counts prior to each dose of Bortezomib for injection. Adjust dose/schedule for thrombocytopenia [see Dosage and Administration (2.4)]. Gastrointestinal and intracerebral hemorrhage has occurred during thrombocytopenia in association with bortezomib. Support with transfusions and supportive care, according to published guidelines.

In the single-agent, relapsed multiple myeloma study of bortezomib versus dexamethasone, the mean platelet count nadir measured was approximately 40% of baseline. The severity of thrombocytopenia related to pretreatment platelet count is shown in Table 6. The incidence of bleeding (≥ Grade 3) was 2% on the bortezomib arm and was < 1% in the dexamethasone arm. 

Table 6: Severity of Thrombocytopenia Related to Pretreatment Platelet Count in the Relapsed Multiple Myeloma Study of Bortezomib versus Dexamethasone

* A baseline platelet count of 50,000/μL was required for study eligibility 

** Data were missing at baseline for one patient
PURPOSE: As United States healthcare transitions from traditional fee-for-service models to value-based care, there is increased need to demonstrate quality care through clinical outcomes. Therefore, the purpose of this study was to create equations to calculate an expected mobility score for lower limb prosthesis users specific to their age, etiology, and amputation level to provide benchmarks to qualify good outcomes.
MATERIALS AND METHODS: A retrospective cross-sectional analysis of outcomes collected during clinical care was performed. Individuals were grouped based on amputation level (unilateral above-knee (AKA) or below-knee (BKA)) and etiology (trauma or diabetes/dysvascular (DV)). The mean mobility score (PLUS-M® T-score) for each year of age was calculated. AKAs were further stratified into having a microprocessor knee (MPK) or non-microprocessor (nMPK) for secondary analysis.
RESULTS: As expected, average prosthetic mobility declined with age. Overall, BKAs had higher PLUS-M T-scores compared to AKAs and trauma etiologies had higher scores compared to DV. For AKAs, those with a MPK had higher T-scores compared to those with a nMPK.
CONCLUSIONS: Results from this study provide average mobility for adult patients across every year of life. This can be leveraged to create a mobility adjustment factor to qualify good outcomes in lower limb prosthetic care.
Participants randomized to the waiting list control group receive no educational intervention for the duration of the 10 weeks. During this period participants can receive standard treatment, consisting of diagnostic treatment with medication.
Participants will receive a session of active HD-tDCS at a current intensity of 4 mA for a duration of 15min. The placement of electrodes will be determined to specifically target the primary motor cortex (4 x 1 montage with the anode over C4). During the stimulation, participants will be engaged in a mental training task (sequential finger tapping-task).
A potential role for fibroblast growth factor receptor 2 (FGFR2) in cutaneous squamous cell carcinoma (cSCC) has been reported. To demonstrate the specific role of FGFR2 in UVB-induced skin carcinogenesis and development of cSCC, we generated a keratinocyte specific, tamoxifen inducible mouse model of FGFR2 deficiency. In this mouse model, topical application of 4-hydroxy tamoxifen led to the induction of Cre recombinase to delete FGFR2 in epidermal keratinocytes of both male and female transgenic mice. Analysis of epidermal protein lysates isolated from FGFR2 deficient mice exposed to UVB showed significant reductions of phospho-FGFR (pFGFR; Y653/654) and phospho-fibroblast growth factor receptor substrate 2α as well as downstream effectors of mTORC1 signaling. Phosphorylation of signal transducer and activators of transcription 1/3 was significantly reduced as well as levels of IRF-1, DUSP6, early growth response 1, and PD-L1 compared to the control groups. Keratinocyte-specific ablation of FGFR2 also significantly inhibited epidermal hyperproliferation, hyperplasia, and inflammation after exposure to UVB. Finally, keratinocyte-specific deletion of FGFR2 significantly inhibited UVB-induced cSCC formation. Collectively, the current data demonstrate an important role of FGFR2 in UVB-induced oncogenic signaling as well as development of cSCC. In addition, the current preclinical findings suggest that inhibition of FGFR2 signaling may provide a previously unreported strategy to prevent and/or treat UVB-induced cSCC.
PURPOSE: To obtain an antiaging agent comprising a soap of a fatty acid alkali metal salt as an active ingredient. CONSTITUTION: This antiaging agent comprises a soap of an alkali metal salt of a saturated or monounsaturated fatty acid containing a 10-22C hydrocarbon chain as an active ingredient. The soap comprises 62.5-64.5 wt.% of a fatty acid or a fatty acid and a resin, 8-8.5 wt.% of a mixture of sodium hydroxide, sodium chloride and glycerol and 28-29 wt.% of water as essential components. The agent is properly formulated with arbitrary components by a routine procedure to prepare a cake, a gel, a cream, a milky lotion, a lotion, a foam, etc. A soap which has been used only as a detergent shows antiaging effects. The application of the agent is to coat a body part to be treated with the agent at least, usually once to four times for several days, for example, 1-5 days. After the application, the part is sufficiently washed with water each time.
Problem Management Plus (PMP) is a low-intensity evidence-based psychological intervention developed by World Health Organization that can be delivered by trained lay people. PMP systematically teaches four strategies: stress management through breathing exercises, problem solving, behavioral activation, and skills to strengthen social support at individual level. The current study plans to adapt PMP to develop the PMP for Immigrants (PMP-I) for a family setting to address immigrant's multiple social and emotional stressors while adjusting into the new multi-cultural environment of the United States. The rationale to adapt PMP is based on our intervention model that demands integration of social and emotional stressors; promising results of PMP; strong evidence of family and community ties in health care process; and growing consensus among community, scientists, and policymakers on the need for family-based care models that are sustainable. PMP-I is a 5-week, peer-led, culturally tailored mental health promotion program that includes psychoeducation, behavioral activation, and problem solving (90 minutes/session/weekly), and breathing exercises and yoga (90 minutes/session/weekly) in a family setting. Participating families will be randomly allocated into two groups (N=116 families (232 participants: two eligible members per family); 58 families per intervention (PMP-I) and control (CSS)) with assessments at baseline, post-intervention, and 3-month post-intervention with trained community facilitators in collaboration with church leaders.
Background & objectives Overuse injury is an important public health issue among children and adolescents, which may affect their overall performance. Therefore, the objective is to determine the prevalence and compare overuse injuries among school-going children in hill and valley, rural and urban areas of Manipur and identify factors contributing to overuse injuries. Methods After obtaining approval from school authorities, a cross-sectional study was conducted in three districts of Manipur namely, Imphal West, Bishnupur, and Ukhrul, among 3,600 schoolchildren in the age group of 7-15 yr. An interview schedule using a pretested questionnaire and a proforma was used for data collection. Descriptive statistics were used, such as mean, SD, percentages, etc. Results In this study, 3,600 students participated; the mean age was 13.37 yr. The overall prevalence of overuse injury was 14.39 per cent, which was the highest in Imphal West (50.19%) and among males (53.09%). The commonest overuse injuries were of lower extremities (44.98%) and were observed to be the highest in Bishnupur (49.59%) and among males (45.45%). Back pain was more prevalent in Ukhrul (37.78%) and among females (31.69%). Among lower extremity injuries, the majority had chondromalacia patellae (29.18%) and shin splint (24.03%), and among the upper extremity injuries, 81.25 per cent had neck and arm pain. Interpretation & conclusions The overall prevalence of overuse injuries was 14.39 per cent, and the highest was in Imphal West. We observed a paradigm shift as the students' back, neck and arm pain increased. These are important public health concerns that need immediate attention, as well as the development of innovative interventions, including health education and appropriate regulations.
An optical system comprises a wearable device for measuring one or more physiological parameters. The physiological parameters may change in response to stretching of the hand or movement of fingers or thumb of the user, or the parameters may be related to blood constituents or blood flow. The wearable device comprises a light source with a plurality of semiconductor diodes and a detection system that measures reflected light from tissue comprising skin. The semiconductor diodes may be light emitting diodes or laser diodes. The signal to noise ratio for the output signal may be improved by synchronizing the detection system to the light source, increasing light intensity of at least one of the plurality of semiconductor diodes from an initial light intensity, and using change detection that compares light on versus light off for the detection system output. The wearable device is also configured to identify an object.
An absorbent article worn by a wearer adjacent the skin comprises a chassis comprising an outer covering layer comprising a back sheet, liquid pervious top sheet joined to the back sheet and an absorbent core positioned between the back sheet and top sheet. A cuff joined to the chassis has a first surface and a second surface opposite the first surface and contains a skin care composition on the cuff. The composition is a solid or a semisolid at 20[deg]C and is at least partially transferable to a wearer's skin. The skin care composition preferably comprises: (i) 10-95% emollient having a plastic or fluid consistency at 20[deg]C and (ii) 5-90% of an agent capable of immobilising the emollient on the cuff. The emollient comprises petroleum based emollients, fatty acid ester emollients, polysiloxane emollients, sucrose ester fatty acid emollients, and/or alkyl ethoxylate emollients. The immobilising agent is selected from polyhydroxy fatty acid esters, polyhydroxy fatty acid amides, 14-22C fatty alcohols, 12-22C fatty acids, and/or 12-22C fatty alcohol ethoxylates.
INCN039110 400 mg QD for 20 weeks. Subjects without clinical response after four weeks will increase to 600mg QD.
Acute myeloid leukemia (AML) is a genetically heterogeneous disease with a highly variable prognosis and an overall high mortality rate. The 5-year overall survival of adult AML patients is less than 50%, and only 20% of elderly patients survive over 2 years. Acute promyelocytic leukemia (APL) accounts for 10% - 15% of acute myeloid leukemia. Arsenic and ATRA are very effective treatments for APL, a distinct AML subtype characterized by the expression of the PML/RARA fusion protein. PML/RARA expression disrupts PML NBs and blunts p53 signaling, which contributes to increased self-renewal of myeloid progenitors. The application of all-trans retinoic acid (ATRA) and arsenic modifies APL from highly fatal to highly curable. Both RA and arsenic induce degradation of PML/RARA through distinct pathways. Nucleophosmin-1(NPM1) is the most frequently mutated gene in acute myeloid leukemia (AML). According to El Hajj's research, RA or arsenic trioxide synergistically induces proteasomal degradation of mutant NPM1 in AML cell lines or primary samples, leading to differentiation and apoptosis. Combined ATRA/arsenic treatment significantly reduced bone marrow blasts in 3 AML patients and restored the subnuclear localization of both NPM1 and PML. Overall, there is no consensus yet as to whether the addition of ATRA/arsenic improves the outcome of patients with NPM1 mutant AML. However, it still needs clinical research to confirm. The investigators design a clinical trial to prove that arsenic plus ATRA is possibly improving the symptoms of AML patients, reduce early mortality, and extending overall survival time.
FIELD: medicine, biochemistry, pharmacy. SUBSTANCE: invention relates to pharmacologically acceptable composition for inhibition of activity of NO-synthase in mammal that comprises mercapto- or selenoderivative and pharmaceutically acceptable carrier. Invention relates to also method of inhibition of activity of NO-synthase, in part, method that inhibits activity of inducible isoform of NO-synthase selectively. Invention relates to also treatment of different states where inhibition of biosynthesis of nitrogen oxide is expediently by administration in mammal of mercapto- or selenoderivative in pure form or in pharmaceutically acceptable carrier. EFFECT: enhanced effectiveness of treatment. 45 cl, 10 dwg, 6 tbl
Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. The risk of developing muscle-invasive or metastatic bladder cancer increases the longer cystectomy is delayed in the presence of persisting CIS.

Of the patients with CIS treated with ADSTILADRIN on Study CS-003 who underwent subsequent radical cystectomy and for whom pathologic data were available, 14% (n = 6) had muscle-invasive (T2 or greater) disease at cystectomy. Median time from persistence or recurrence of CIS to cystectomy in these patients was 235 days (range 38 to 582 days). Two additional patients who did not undergo cystectomy experienced progression to muscle-invasive disease during the treatment period.

If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.
The patients is going to undergo trials of spontaneous breathing with automatic tube compensation plus continuous positive airway pressure and later a trial with continuous positive airway pressure. During 30 minutes.
Standard Induction (28 Days). M3 Marrow at Day 28 and Off Protocol Therapy.
Research has shown that seeing positive facial expressions towards food are effective for increasing children's desire to eat foods rated as disliked. However, the effect of adults' positive facial expressions whilst eating a raw vegetable on children's acceptance and consumption of nutritious foods that are less preferred (e.g., vegetables) remains to be established. This study examined the effect of unfamiliar adult models' facial expressions eating raw broccoli on children's acceptance and consumption of raw broccoli. Children aged 4-6-year-olds were randomised to watch a video of unfamiliar adult models eating raw broccoli with a positive or neutral facial expression, or a non-food control video. Children's acceptance (willingness to try and frequency of taste exposures) and consumption of raw broccoli was assessed. Data about parent and child characteristics was provided by parents.
The application provides a virtual surface generation method suitable for manual and automatic focusing and application thereof, which are used for constructing a precise focusing model of a pathological image. The method first calculates a manually selected inter-focal-point distance and determines a grid size based on the camera field of view width and height. Then, the focus is divided into connected areas and assigned to the respective small sample masks. Then, for each small sample and automatically generated focal point, a local virtual surface is created and a continuous surface is formed by subdivision meshes, triangulation, and neighborhood point connections. Combining the local virtual surfaces by adopting an average method aiming at the overlapped area; for small grids where virtual faces are not recorded, the adjacent grids are duplicated and mean filling is performed. And finally, calculating the focus value of the blank area by using the inverse distance, and performing smoothing treatment on the virtual surface so as to generate a complete and accurate virtual surface structure.
After obtaining informed consent, cervical and urine specimens will be obtained from all enrolled participants. Cervical biopsies in the disease group will be carried out at the providers' discretion per routine colposcopy protocols. Cervical specimens will be collected by the attending gynecologists and urine samples will be collected by the participants. Aliquots of urine and cervical samples will be tested for HPV DNA with cobas 4800 HPV test (Roche Diagnostics) serving as the gold standard at the Newfoundland Public Health Laboratory, St. John's, Newfoundland. The cobas test, however, identifies only two (types 16 and 18) of 14 high-risk HPV genotypes specifically. Therefore, a second set of aliquots will be tested at Seegene laboratory in Kitchener, Ontario to obtain complete genotype profile of all 14 high-risk genotypes as well as quantitative HPV results using Anyplex HPV DNA test (Seegene Inc), a next generation HPV test. Urine samples will also be independently tested by Infrared (IR) Spectroscopy and signals analyzed by Prof. Rehman's lab, Department of Engineering, Lancaster University, Lancaster United Kingdom (UK) to detect HPV. Spectroscopy results will be compared with HPV test results with genotypes to determine concordance between specimen types and between the testing technologies, with a special reference to urine testing. Biopsy confirmed CIN2+ will serve as the clinical endpoint to determine the sensitivity and specificity of urine spectroscopy testing in comparison with urine HPV testing; cervical HPV results will serve as the reference method. We are partnering with NSV-Tech a biotechnology company based in the US and India who have experience with artificial intelligence and cancer screening using tablet-based technology. Spectroscopy signals will be shared with NSV-Tech to develop artificial neural networks (ANN). The spectroscopy outputs linked to the ground-truth (biopsy confirmed abnormal cervical cells (CIN2)+ histology) will be used to develop ANN to improve diagnostic accuracy of this clinically relevant endpoint and remove subjectivity. The study relies on the ability for spectroscopy to detect HPV. The research team is confident this will be feasible. As noted, members of the research team are reviewing reference urine samples previously analyzed using standard HPV detection methods to confirm that spectroscopy is a viable option method. The control specimen collection and analysis uses standard methods. The data collection will take place in an academic colposcopy clinic with adequate patient volume and a proven track record in recruiting patients for such trials. The analysis of the spectroscopy in the UK of the spectroscopy, is in labs that have significant experience in assessing biological samples. The project's international collaboration is significant and brings together world class leaders in the prevention of cervical cancer who all have experience with novel technology and screening trials.
Patients with myocardial infarction have a much worse prognosis when they have myocardial ischemia-reperfusion (I/R) injury. Further research into the molecular basis of myocardial I/R injury is therefore urgently needed, as well as the identification of novel therapeutic targets and linkages to interventions. Three cysteine residues are present in DJ-1 at amino acids 46, 53, and 106 sites, with the cysteine at position 106 being the most oxidation-prone. This study sought to understand how oxidized DJ-1(C106) contributes to myocardial I/R damage. Rats' left anterior descending branches were tied off to establish a myocardial I/R model in vivo. A myocardial I/R model in vitro was established via anoxia/reoxygenation (A/R) of H9c2 cells. The results showed that autophagy increased after I/R, accompanied by the increased expression of oxidized DJ-1 (ox-DJ-1). In contrast, after pretreatment with NAC (N-acetylcysteine, a ROS scavenger) or Comp-23 (Compound-23, a specific antioxidant binding to the C106 site of DJ-1), the levels of ox-DJ-1, autophagy and LDH release decreased, and cell survival rate increased. Furthermore, the inhibition of interaction between ox-DJ-1 and PTEN could increase PTEN phosphatase activity, inhibit the p-IKK/NF-κB/Beclin1 pathway, reduce injurious autophagy, and alleviate A/R injury. However, BA (Betulinic acid, a NF-κB agonist) was able to reverse the protective effects produced by Comp-23 pretreatment. In conclusion, ox-DJ-1 could activate detrimental autophagy through the PTEN/p-IKK/NF-κB/Beclin1 pathway and exacerbate myocardial I/R injury.